250
Participants
Start Date
October 1, 2024
Primary Completion Date
June 30, 2028
Study Completion Date
December 31, 2030
Nadofaragene Firadenovec
vector-based gene therapy for NMIBC treatment to potentiate durable therapeutic responses by interferon (IFN) alfa-2b (IFN-α2b) amplification. It is a non-replicating recombinant adenovirus serotype 5 vector containing a transgene encoding the human IFN-α2b gene.
Gemcitabine
Intravesical Gemcitabine chemotherapy, used in combination with Docetaxel.
Docetaxel
Intravesical Docetaxel chemotherapy, used in combination with Gemcitabine.
Pembrolizumab
Pembrolizumab is an FDA approved immune checkpoint inhibitor which restores the anti-tumour immune response by blocking the programmed cell death protein 1 (PD-1). Pembrolizumab is administered via intravenous (IV) infusion.
RECRUITING
James J. Peters VA Medical Center, The Bronx
RECRUITING
Northwell Health -The Arthur Smith Institute for Urology, Lake Success
RECRUITING
Premier Medical Group of the Hudson Valley, Poughkeepsie
RECRUITING
Great Lakes Physician PC d/b/a Western new York Urology Associates, Cheektowaga
RECRUITING
Roswell Park Cancer Institute, Buffalo
RECRUITING
MidLantic Urology, Bala-Cynwyd
RECRUITING
Carolina Urologic Research Center, Myrtle Beach
RECRUITING
Emory University, Atlanta
RECRUITING
Georgia Urology, Atlanta
RECRUITING
University of Cincinnati, Cincinnati
RECRUITING
Indiana University, Indianapolis
RECRUITING
Ferring Investigational Site, Troy
RECRUITING
Wichita Urology Group, Wichita
RECRUITING
Houston Methodist Hospital (Houston), Houston
RECRUITING
Boise VA Medical Center, Boise
RECRUITING
American Institute of Research, Los Angeles
RECRUITING
USC Kenneth Norris Jr Cancer Hospital, Los Angeles
RECRUITING
Genesis Research, LLC - San Diego, San Diego
RECRUITING
University of California, Irvine, Orange
RECRUITING
Yale School of Medicine, New Haven
RECRUITING
Atlantic Health, Morristown
Lead Sponsor
Ferring Pharmaceuticals
INDUSTRY